GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Equity-to-Asset
中文

Emergent BioSolutions (Emergent BioSolutions) Equity-to-Asset : 0.36 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Emergent BioSolutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $649 Mil. Emergent BioSolutions's Total Assets for the quarter that ended in Dec. 2023 was $1,823 Mil. Therefore, Emergent BioSolutions's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.36.

The historical rank and industry rank for Emergent BioSolutions's Equity-to-Asset or its related term are showing as below:

EBS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36   Med: 0.52   Max: 0.85
Current: 0.36

During the past 13 years, the highest Equity to Asset Ratio of Emergent BioSolutions was 0.85. The lowest was 0.36. And the median was 0.52.

EBS's Equity-to-Asset is ranked worse than
76.17% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs EBS: 0.36

Emergent BioSolutions Equity-to-Asset Historical Data

The historical data trend for Emergent BioSolutions's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Equity-to-Asset Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.50 0.55 0.44 0.36

Emergent BioSolutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.41 0.44 0.37 0.36

Competitive Comparison of Emergent BioSolutions's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Equity-to-Asset falls into.



Emergent BioSolutions Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Emergent BioSolutions's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=649.3/1823.2
=0.36

Emergent BioSolutions's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=649.3/1823.2
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions  (NYSE:EBS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Emergent BioSolutions Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (Emergent BioSolutions) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Executives
Neal Franklin Fowler director C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel officer: SVP, Bioservices 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii officer: Interim CEO EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams officer: SVP, Products Business 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal director C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen officer: EVP, Quality & Ethics, and CPL 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox officer: EVP, Ext Aff, GC, Corp Sec 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl officer: EVP, Chief Financial Officer NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey officer: EVP, BioDefense Division 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer officer: Interim, EVP, BioSciences 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850

Emergent BioSolutions (Emergent BioSolutions) Headlines

From GuruFocus

Emergent BioSolutions to Participate in Investor Conferences

By PurpleRose PurpleRose 08-10-2022